Trial Information

Frequency of Epidermal Growth Factor Receptor Mutations in Latinos/Hispanics With Non-Small Lung Cancer

Background:

There is a growing body of evidence that points to genetic heterogeneity of the EGFR pathway
in non-small cell lung cancer among different ethnic groups and that underscores the need
for consideration of these differences in patient management and in the design of future
trials of agents that target the EGFR pathway. Activating mutations in EGFR have been found
in about 15% of NSCLC patients from North America and Europe, 40% of Asian and 2% in
African-Americans. However, there is no data on the frequency of EGFR mutations in U.S.
Hispanic and Latin American patients with NSCLC.

Primary Protocol Objectives:

- To determine the frequency of EGFR mutations in Hispanic/Latinos with non-small cell
lung cancer according to gender and smoking status.

- To study the association between the frequency of EGFR mutations and the percentage of
American Indian ancestry, as defined by genetic ancestry analysis, in Hispanic/Latinos
with non-small cell lung cancer.

Secondary Protocol Objectives:

-To evaluate the association between EGFR mutations and other clinical variables such as
wood smoke exposure, age, stage at presentation, nationality and response to EGFR TKIs.

Eligibility:

Hispanic or Latino patients with histologically confirmed non-small cell lung cancer.

Design:

Paraffin embedded tumor samples from Latino patients with non-small cell lung cancer will be
collected at the NIH's clinical center and the participating institutions.

Samples and clinical data will then be sent to the molecular pathology laboratory for EGFR
mutation analyses. The remainder DNA will then used for genetic ancestry analysis.